IL228770A0 - Processes and intermaediates - Google Patents
Processes and intermaediatesInfo
- Publication number
- IL228770A0 IL228770A0 IL228770A IL22877013A IL228770A0 IL 228770 A0 IL228770 A0 IL 228770A0 IL 228770 A IL228770 A IL 228770A IL 22877013 A IL22877013 A IL 22877013A IL 228770 A0 IL228770 A0 IL 228770A0
- Authority
- IL
- Israel
- Prior art keywords
- intermaediates
- processes
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
- C07D451/14—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing 9-azabicyclo [3.3.1] nonane ring systems, e.g. granatane, 2-aza-adamantane; Cyclic acetals thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/52—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring condensed with a ring other than six-membered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0802—Tripeptides with the first amino acid being neutral
- C07K5/0812—Tripeptides with the first amino acid being neutral and aromatic or cycloaliphatic
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/02—Linear peptides containing at least one abnormal peptide link
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Virology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Epidemiology (AREA)
- Emergency Medicine (AREA)
- AIDS & HIV (AREA)
- Tropical Medicine & Parasitology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Indole Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyrrole Compounds (AREA)
- Enzymes And Modification Thereof (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US70996405P | 2005-08-19 | 2005-08-19 | |
US81004206P | 2006-06-01 | 2006-06-01 | |
PCT/US2006/032481 WO2007022459A2 (en) | 2005-08-19 | 2006-08-18 | Processes and intermediates |
Publications (1)
Publication Number | Publication Date |
---|---|
IL228770A0 true IL228770A0 (en) | 2013-12-31 |
Family
ID=37708299
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IL189585A IL189585A (en) | 2005-08-19 | 2008-02-18 | Processes for the preparation of protease inhibitors and intermediates made by such processes |
IL228770A IL228770A0 (en) | 2005-08-19 | 2013-10-07 | Processes and intermaediates |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IL189585A IL189585A (en) | 2005-08-19 | 2008-02-18 | Processes for the preparation of protease inhibitors and intermediates made by such processes |
Country Status (25)
Country | Link |
---|---|
US (3) | US7776887B2 (en) |
EP (4) | EP2364970A1 (en) |
JP (1) | JP5203203B2 (en) |
KR (4) | KR20130110236A (en) |
CN (2) | CN101291909B (en) |
AR (1) | AR058025A1 (en) |
AT (1) | ATE463480T1 (en) |
AU (1) | AU2006279357B2 (en) |
BR (1) | BRPI0615029A2 (en) |
CA (1) | CA2619659A1 (en) |
CY (2) | CY1110214T1 (en) |
DE (1) | DE602006013492D1 (en) |
DK (2) | DK1934179T3 (en) |
ES (2) | ES2449268T3 (en) |
HK (2) | HK1122801A1 (en) |
IL (2) | IL189585A (en) |
NZ (3) | NZ593214A (en) |
PL (3) | PL2194043T3 (en) |
PT (2) | PT2194043E (en) |
RU (2) | RU2446171C2 (en) |
SG (1) | SG2014013338A (en) |
SI (2) | SI2194043T1 (en) |
TW (2) | TWI391376B (en) |
WO (1) | WO2007022459A2 (en) |
ZA (1) | ZA200801791B (en) |
Families Citing this family (70)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
UA79749C2 (en) * | 1996-10-18 | 2007-07-25 | Vertex Pharma | Inhibitors of serine proteases, particularly hepatitis c virus ns3 protease |
SV2003000617A (en) * | 2000-08-31 | 2003-01-13 | Lilly Co Eli | INHIBITORS OF PROTEASA PEPTIDOMIMETICA REF. X-14912M |
AR045596A1 (en) * | 2003-09-05 | 2005-11-02 | Vertex Pharma | INHIBITORS OF SERINE PROTEASES IN PARTICULAR HCV PROTEASA NS3-NS4A |
MX2008001528A (en) * | 2005-08-02 | 2008-04-04 | Vertex Pharma | Inhibitors of serine proteases. |
KR20130110236A (en) | 2005-08-19 | 2013-10-08 | 버텍스 파마슈티칼스 인코포레이티드 | Processes and intermediates |
US8399615B2 (en) | 2005-08-19 | 2013-03-19 | Vertex Pharmaceuticals Incorporated | Processes and intermediates |
AR055395A1 (en) * | 2005-08-26 | 2007-08-22 | Vertex Pharma | INHIBITING COMPOUNDS OF THE ACTIVITY OF SERINA PROTEASA NS3-NS4A OF HEPATITIS C VIRUS |
US7964624B1 (en) * | 2005-08-26 | 2011-06-21 | Vertex Pharmaceuticals Incorporated | Inhibitors of serine proteases |
WO2007098270A2 (en) | 2006-02-27 | 2007-08-30 | Vertex Pharmaceuticals Incorporated | Co-crystals comprising vx-950 and pharmaceutical compositions comprising the same |
EP2194039A1 (en) | 2006-03-16 | 2010-06-09 | Vertex Pharmceuticals Incorporated | Process for preparing optically enriched compounds |
SG170729A1 (en) * | 2006-03-16 | 2011-05-30 | Vertex Pharma | Processes and intermediates for preparing steric compounds |
US8222427B2 (en) * | 2006-12-15 | 2012-07-17 | Merck Sharp & Dohme Corp. | Bisulfite purification of an alpha-keto amide |
WO2008106058A2 (en) * | 2007-02-27 | 2008-09-04 | Vertex Pharmaceuticals Incorporated | Inhibitors of serine proteases |
KR20090115970A (en) * | 2007-02-27 | 2009-11-10 | 버텍스 파마슈티칼스 인코포레이티드 | Co-crystals and pharmaceutical compositions comprising them |
TW200922933A (en) * | 2007-08-30 | 2009-06-01 | Vertex Pharma | Co-crystals and pharmaceutical compositions comprising the same |
WO2009114633A1 (en) * | 2008-03-12 | 2009-09-17 | Virobay, Inc. | Process for the preparation of (3s)-3-amino-n-cyclopropyl-2-hydroxyalkanamide derivatives |
WO2009152474A2 (en) * | 2008-06-13 | 2009-12-17 | Virobay, Inc. | Process for the preparation of (3s)-3-amino-n-cyclopropyl-2-hydroxyalkanamide derivatives |
CA2728226A1 (en) | 2008-06-24 | 2010-01-21 | Codexis, Inc. | Biocatalytic processes for the preparation of substantially stereomerically pure fused bicyclic proline compounds |
MX2012009926A (en) * | 2010-02-25 | 2012-10-05 | Vereniging Voor Christelijk Hoger Onderwijs Wetenschappelijk Onderzoek En Patientenzorg | A process for the preparation of substituted prolyl peptides and similar peptidomimetics. |
WO2011153423A2 (en) * | 2010-06-03 | 2011-12-08 | Vertex Pharmaceuticals Incorporated | Processes and intermediates |
CN102167680B (en) * | 2011-03-23 | 2014-07-02 | 合亚医药科技(上海)有限公司 | Preparation method of octahydrocyclopenta[c]pyrrole carboxylic acid derivative |
CN103814001A (en) * | 2011-05-13 | 2014-05-21 | 弗特克斯药品有限公司 | Processes and intermediates |
EP2707346A1 (en) * | 2011-05-13 | 2014-03-19 | Vertex Pharmaceuticals Inc. | Process for the preparation of protease inhibitors |
JP2013010738A (en) * | 2011-05-31 | 2013-01-17 | Sumitomo Chemical Co Ltd | Method for producing ester compound |
PH12014500832A1 (en) | 2011-10-21 | 2022-12-02 | Abbvie Inc | Methods for treating hcv |
US8492386B2 (en) | 2011-10-21 | 2013-07-23 | Abbvie Inc. | Methods for treating HCV |
US8466159B2 (en) | 2011-10-21 | 2013-06-18 | Abbvie Inc. | Methods for treating HCV |
JP5677646B2 (en) | 2011-10-21 | 2015-02-25 | アッヴィ・インコーポレイテッド | DAA combination therapy (eg, with ABT-072 or ABT-333) for use in the treatment of HCV |
US20130123276A1 (en) | 2011-11-14 | 2013-05-16 | Sven Ruf | Use of telaprevir and related compounds in atherosclerosis, heart failure, renal diseases, liver diseases or inflammatory diseases |
CN103183632A (en) * | 2011-12-29 | 2013-07-03 | 山东方明药业集团股份有限公司 | Purification method of 3-azabicyclo-octane hydrochloride |
ITMI20120192A1 (en) | 2012-02-13 | 2013-08-14 | Dipharma Francis Srl | PROCEDURE FOR THE PREPARATION OF AN INHIBITOR OF VIRAL AND INTERMEDIATE PROTEASIS |
ITMI20120359A1 (en) | 2012-03-07 | 2013-09-08 | Dipharma Francis Srl | PROCEDURE FOR THE PREPARATION OF USEFUL INTERMEDIATES IN THE PREPARATION OF A VIRAL PROTEASIS INHIBITOR |
ITMI20121668A1 (en) * | 2012-10-05 | 2014-04-06 | Dipharma Francis Srl | SUMMARY OF AN INTERMEDIATE OF AN ANTIVIRAL COMPOUND |
ITMI20120391A1 (en) * | 2012-03-13 | 2013-09-14 | Dipharma Francis Srl | PROCEDURE FOR THE SYNTHESIS OF A USEFUL CYCLOPROPYLAMID INTERMEDIATE IN THE PREPARATION OF A VIRAL PROTEASIS INHIBITOR |
WO2013136265A1 (en) | 2012-03-13 | 2013-09-19 | Dipharma Francis S.R.L. | Synthesis of an intermediate of an antiviral compound |
US20150038677A1 (en) | 2012-03-16 | 2015-02-05 | Sandoz Ag | Process for the synthesis of telaprevir, or pharmaceutically acceptable salts or solvates as well as intermediate products thereof |
ITMI20120608A1 (en) | 2012-04-13 | 2013-10-14 | Dipharma Francis Srl | PROCEDURE FOR THE PREPARATION OF AN INHIBITOR OF VIRAL PROTEASES IN AMORPHOUS FORM |
ITMI20120800A1 (en) * | 2012-05-10 | 2013-11-11 | Dipharma Francis Srl | PROCEDURE FOR THE PREPARATION OF A USEFUL INTERMEDIATE IN THE PREPARATION OF A VIRAL PROTEASIS INHIBITOR |
CN103450066B (en) * | 2012-05-30 | 2017-03-15 | 博瑞生物医药(苏州)股份有限公司 | The preparation method of Telaprevir intermediate |
WO2013178682A2 (en) | 2012-05-30 | 2013-12-05 | Chemo Ibérica, S.A. | Multicomponent process for the preparation of bicyclic compounds |
ITMI20120990A1 (en) * | 2012-06-07 | 2013-12-08 | Dipharma Francis Srl | SYNTHESIS OF A VIRAL PROTEASIS INHIBITOR |
WO2013189980A1 (en) | 2012-06-20 | 2013-12-27 | Sandoz Ag | SYNTHESIS OF TELAPREVIR AND BOCEPREVIR, OR PHARMACEUTICALLY ACCEPTABLE SALTS OR SOLVATES AS WELL AS INTERMEDIATE PRODUCTS THEREOF INCLUDING ß-AMINO ACIDS PREPARED VIA MUKAIYAMA ALDOL ADDITION |
WO2013189978A1 (en) | 2012-06-20 | 2013-12-27 | Sandoz Ag | PROCESS FOR PREPARING ß-AMINO ACID DERIVATIVES AND USE OF SAID PROCESS FOR PREPARING TELAPREVIR |
WO2014019179A1 (en) * | 2012-08-01 | 2014-02-06 | 上海迪赛诺药业有限公司 | Method for preparing telaprevir and intermediate thereof |
WO2014033667A1 (en) | 2012-08-30 | 2014-03-06 | Ranbaxy Laboratories Limited | Process for the preparation of telaprevir |
CN102875648B (en) * | 2012-09-26 | 2014-02-19 | 深圳翰宇药业股份有限公司 | Method for preparing telaprevir |
WO2014053533A1 (en) | 2012-10-05 | 2014-04-10 | Sanofi | Use of substituted 3-heteroaroylamino-propionic acid derivatives as pharmaceuticals for prevention/treatment of atrial fibrillation |
ITMI20122036A1 (en) | 2012-11-29 | 2014-05-30 | Dipharma Francis Srl | SUMMARY OF AN INTERMEDIATE OF AN ANTIVIRAL COMPOUND |
WO2014096374A1 (en) | 2012-12-21 | 2014-06-26 | Sandoz Ag | Process for the synthesis of pyrrolidines and pyrroles |
US20160039871A1 (en) * | 2012-12-21 | 2016-02-11 | Sandoz Ag | Novel forms of telaprevir |
CN103936651B (en) * | 2013-01-18 | 2016-06-22 | 上海医药工业研究院 | Intermediate III of anti-hepatitis C medicine Boceprevir and its preparation method and application |
ITMI20130706A1 (en) * | 2013-04-30 | 2014-10-31 | Dipharma Francis Srl | PROCEDURE FOR THE PREPARATION OF AN INHIBITOR OF VIRAL AND INTERMEDIATE PROTEASIS |
CN103288671B (en) * | 2013-06-20 | 2014-10-29 | 上海步越化工科技有限公司 | Synthetic method of (3S)-3-amino-N-cyclopropyl-2-hydroxyhexanamide hydrochloride |
WO2014203208A1 (en) | 2013-06-21 | 2014-12-24 | Ranbaxy Laboratories Limited | Process for the preparation of telaprevir and intermediates thereof |
WO2014203224A1 (en) | 2013-06-21 | 2014-12-24 | Ranbaxy Laboratories Limited | Process for the preparation of telaprevir and its intermediates |
CN104292146B (en) * | 2013-06-24 | 2017-04-26 | 上海医药工业研究院 | Telaprevir intermediate and preparation method thereof |
CN103342656B (en) * | 2013-07-04 | 2015-04-08 | 苏州永健生物医药有限公司 | Synthesis method of Telaprevir intermediate |
CN103435532B (en) * | 2013-09-02 | 2015-07-08 | 苏州永健生物医药有限公司 | Synthetic method of boceprevir intermediate |
WO2015036522A1 (en) * | 2013-09-13 | 2015-03-19 | Sandoz Ag | Process for the preparation and isolation of (s)-3-amino-n-cyclopropyl-2,2-dialkoxyhexanamide and (s)-tert-butyl(1-(cyclopropylamino)-2,2-dialkoxy-1-oxohexan-3-yl)carbamate and use thereof for the preparation of telaprevir |
JP2016539931A (en) * | 2013-10-23 | 2016-12-22 | 株式会社カネカ | Tetrapeptide compound and method for producing the same |
CN103664739B (en) * | 2013-12-10 | 2016-04-27 | 湖南科源生物制品有限公司 | A kind of preparation method of Telaprevir intermediate |
US10118890B2 (en) | 2014-10-10 | 2018-11-06 | The Research Foundation For The State University Of New York | Trifluoromethoxylation of arenes via intramolecular trifluoromethoxy group migration |
CN105646329A (en) * | 2014-11-28 | 2016-06-08 | 重庆圣华曦药业股份有限公司 | Method for preparing telaprevir intermediate |
CN105111129A (en) * | 2015-08-24 | 2015-12-02 | 上海合全药业股份有限公司 | Preparation method of (1S, 3aR, 6aS)-octahydro cyclopenta [C] pyrrole-1-carboxylic acid tert-butyl ester oxalate |
CN105601556B (en) * | 2015-12-02 | 2018-11-13 | 镇江市高等专科学校 | The preparation method of telavi bicyclic pyrrole alkane intermediate |
EP3448392A4 (en) | 2016-04-28 | 2020-01-15 | Emory University | ALKYNOUS THERAPEUTIC NUCLEOTIDE AND NUCLEOSIDE COMPOSITIONS AND RELATED APPLICATIONS |
JP7584418B2 (en) | 2018-12-04 | 2024-11-15 | ブリストル-マイヤーズ スクイブ カンパニー | Analysis method using in-sample calibration curves by multiple reaction isotope molecular species reaction monitoring |
KR20230038457A (en) | 2020-06-10 | 2023-03-20 | 알리고스 테라퓨틱스 인코포레이티드 | Antiviral compounds for treating coronavirus, picornavirus and norovirus infections |
KR20240035513A (en) | 2021-07-09 | 2024-03-15 | 알리고스 테라퓨틱스 인코포레이티드 | antiviral compounds |
WO2023043816A1 (en) | 2021-09-17 | 2023-03-23 | Aligos Therapeutics, Inc. | Anti-viral compounds for treating coronavirus, picornavirus, and norovirus infections |
Family Cites Families (48)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3211676A1 (en) * | 1982-03-30 | 1983-10-06 | Hoechst Ag | NEW DERIVATIVES OF CYCLOALKA (C) PYRROL CARBONIC ACIDS, METHOD FOR THE PRODUCTION THEREOF, THEIR SUBSTANCES AND THE USE THEREOF AND NEW CYCLOALKA (C) PYRROL CARBONIC ACIDS AS THE INTERMEDIATE LEVELS AND METHODS |
US5468858A (en) * | 1993-10-28 | 1995-11-21 | The Board Of Regents Of Oklahoma State University Physical Sciences | N-alkyl and n-acyl derivatives of 3,7-diazabicyclo-[3.3.1]nonanes and selected salts thereof as multi-class antiarrhythmic agents |
JPH0967344A (en) * | 1995-09-05 | 1997-03-11 | Koei Chem Co Ltd | Process for producing optically active N-benzyloxycarbonylpipecolic acid |
EP0907659A1 (en) | 1996-05-10 | 1999-04-14 | Schering Corporation | Synthetic inhibitors of hepatitis c virus ns3 protease |
JP3863230B2 (en) | 1996-08-16 | 2006-12-27 | 株式会社カネカ | Process for producing β-amino-α-hydroxy acid derivative |
UA79749C2 (en) | 1996-10-18 | 2007-07-25 | Vertex Pharma | Inhibitors of serine proteases, particularly hepatitis c virus ns3 protease |
GB9623908D0 (en) | 1996-11-18 | 1997-01-08 | Hoffmann La Roche | Amino acid derivatives |
GB9707659D0 (en) | 1997-04-16 | 1997-06-04 | Peptide Therapeutics Ltd | Hepatitis C NS3 Protease inhibitors |
IL134232A0 (en) | 1997-08-11 | 2001-04-30 | Boehringer Ingelheim Ca Ltd | Hepatitis c inhibitor peptides |
ES2234144T3 (en) | 1997-08-11 | 2005-06-16 | Boehringer Ingelheim (Canada) Ltd. | ANALOGS OF INHIBITING PEPTIDES OF HEPATITIS C. |
US6767991B1 (en) * | 1997-08-11 | 2004-07-27 | Boehringer Ingelheim (Canada) Ltd. | Hepatitis C inhibitor peptides |
IT1299134B1 (en) | 1998-02-02 | 2000-02-29 | Angeletti P Ist Richerche Bio | PROCEDURE FOR THE PRODUCTION OF PEPTIDES WITH PROTEAS INHIBITING THE NS3 PROTEASIS OF THE HCV VIRUS, PEPTIDES SO OBTAINABLE AND PEPTIDES |
EP1066247B1 (en) | 1998-03-31 | 2006-11-22 | Vertex Pharmaceuticals Incorporated | Inhibitors of serine proteases, particularly hepatitis c virus ns3 protease |
GB9812523D0 (en) | 1998-06-10 | 1998-08-05 | Angeletti P Ist Richerche Bio | Peptide inhibitors of hepatitis c virus ns3 protease |
US6323180B1 (en) | 1998-08-10 | 2001-11-27 | Boehringer Ingelheim (Canada) Ltd | Hepatitis C inhibitor tri-peptides |
DE19836514A1 (en) | 1998-08-12 | 2000-02-17 | Univ Stuttgart | Modification of engineering polymers with N-basic groups and ion exchange groups in the side chain gives membranes of good thermal and mechanical stability useful for fuel cells, diffusion dialysis, electrodialysis, and reverse osmosis |
GB9825946D0 (en) | 1998-11-26 | 1999-01-20 | Angeletti P Ist Richerche Bio | Pharmaceutical compounds for the inhibition of hepatitis C virus NS3 protease |
WO2000055113A1 (en) | 1999-03-12 | 2000-09-21 | Ajinomoto Co.,Inc. | PROCESS FOR THE PREPARATION OF α-AMINOKETONE DERIVATIVES |
UA74546C2 (en) | 1999-04-06 | 2006-01-16 | Boehringer Ingelheim Ca Ltd | Macrocyclic peptides having activity relative to hepatitis c virus, a pharmaceutical composition and use of the pharmaceutical composition |
US6608027B1 (en) | 1999-04-06 | 2003-08-19 | Boehringer Ingelheim (Canada) Ltd | Macrocyclic peptides active against the hepatitis C virus |
US7122627B2 (en) | 1999-07-26 | 2006-10-17 | Bristol-Myers Squibb Company | Lactam inhibitors of Hepatitis C virus NS3 protease |
EP1206449A1 (en) | 1999-07-26 | 2002-05-22 | Bristol-Myers Squibb Company | Lactam inhibitors of hepatitis c virus ns3 protease |
US6699855B2 (en) * | 2000-02-29 | 2004-03-02 | Bristol-Myers Squibb Company | Inhibitors of hepatitis C virus NS3 protease |
AU2001243515A1 (en) * | 2000-03-08 | 2001-09-17 | Rhode Island Hospital, A Lifespan Partner | Combination drug therapy |
JP4806154B2 (en) | 2000-04-03 | 2011-11-02 | バーテックス ファーマシューティカルズ インコーポレイテッド | Inhibitors of serine proteases, especially hepatitis C virus NS3 protease |
MXPA02009920A (en) * | 2000-04-05 | 2003-03-27 | Schering Corp | Macrocyclic ns3 serine protease inhibitors of hepatitis c virus comprising n cyclic p2 moieties. |
CZ20023473A3 (en) | 2000-04-19 | 2003-01-15 | Schering Corporation | Macrocyclic compound and pharmaceutical preparation |
RU2003105221A (en) * | 2000-07-21 | 2004-09-20 | Шеринг Корпорейшн (US) | NEW PEPTIDES AS INHIBITORS OF NS3-SERIN PROTEASES OF HEPATITIS C VIRUS |
AR034127A1 (en) * | 2000-07-21 | 2004-02-04 | Schering Corp | IMIDAZOLIDINONES AS INHIBITORS OF NS3-SERINA PROTEASA OF THE HEPATITIS C VIRUS, PHARMACEUTICAL COMPOSITION, A METHOD FOR THEIR PREPARATION, AND THE USE OF THE SAME FOR THE MANUFACTURE OF A MEDICINAL PRODUCT |
AR029851A1 (en) | 2000-07-21 | 2003-07-16 | Dendreon Corp | NEW PEPTIDES AS INHIBITORS OF NS3-SERINA PROTEASA DEL VIRUS DE HEPATITIS C |
KR100904788B1 (en) | 2000-07-21 | 2009-06-25 | 쉐링 코포레이션 | Novel Peptides as Hepatic C Virus Inhibitors of Ns3-serine Protease |
US7244721B2 (en) * | 2000-07-21 | 2007-07-17 | Schering Corporation | Peptides as NS3-serine protease inhibitors of hepatitis C virus |
SV2003000617A (en) * | 2000-08-31 | 2003-01-13 | Lilly Co Eli | INHIBITORS OF PROTEASA PEPTIDOMIMETICA REF. X-14912M |
US6846806B2 (en) | 2000-10-23 | 2005-01-25 | Bristol-Myers Squibb Company | Peptide inhibitors of Hepatitis C virus NS3 protein |
AU2002248147B2 (en) | 2000-11-20 | 2006-04-06 | Bristol-Myers Squibb Company | Hepatitis C tripeptide inhibitors |
AU2002230763A1 (en) | 2000-12-13 | 2008-01-03 | Bristol-Myers Squibb Pharma Company | Inhibitors of hepatitis c virus ns3 protease |
US6653295B2 (en) | 2000-12-13 | 2003-11-25 | Bristol-Myers Squibb Company | Inhibitors of hepatitis C virus NS3 protease |
AU2002230764A1 (en) | 2000-12-13 | 2002-06-24 | Bristol-Myers Squibb Pharma Company | Imidazolidinones and their related derivatives as hepatitis c virus ns3 protease inhibitors |
GB0107924D0 (en) | 2001-03-29 | 2001-05-23 | Angeletti P Ist Richerche Bio | Inhibitor of hepatitis C virus NS3 protease |
MXPA04000293A (en) | 2001-07-11 | 2004-05-04 | Vertex Pharma | Bridged bicyclic serine protease inhibitors. |
MXPA04003825A (en) * | 2001-10-24 | 2004-07-08 | Vertex Pharma | Inhibitors of serine protease, particularly hepatitis c virus ns3-ns4a protease, incorporating a fused ring system. |
US20040180815A1 (en) | 2003-03-07 | 2004-09-16 | Suanne Nakajima | Pyridazinonyl macrocyclic hepatitis C serine protease inhibitors |
WO2004072243A2 (en) | 2003-02-07 | 2004-08-26 | Enanta Pharmaceuticals, Inc. | Macrocyclic hepatitis c serine protease inhibitors |
RU2006113880A (en) * | 2003-09-26 | 2007-11-20 | Шеринг Корпорейшн (US) | MACROCYCLIC INHIBITORS OF SERIES PROTEINASES NS3 HEPATITIS C VIRUS |
US7365092B2 (en) | 2003-10-10 | 2008-04-29 | Vertex Pharmaceuticals Incorporated | Inhibitors of serine proteases, particularly HCV NS3-NS4A protease |
AR048413A1 (en) | 2004-02-27 | 2006-04-26 | Schering Corp | PROLINA 3,4- (CYCLOPENTIL) COMPOUNDS - FUSIONED, AS INHIBITORS OF SERINA PROTEASA NS3 OF HEPATITIS C VIRUS |
KR20130110236A (en) | 2005-08-19 | 2013-10-08 | 버텍스 파마슈티칼스 인코포레이티드 | Processes and intermediates |
CA2686051A1 (en) * | 2007-05-04 | 2008-11-13 | Vertex Pharmaceuticals Incorporated | Combination therapy for the treatment of hcv infection |
-
2006
- 2006-08-18 KR KR1020137024964A patent/KR20130110236A/en not_active Application Discontinuation
- 2006-08-18 ES ES10155058.0T patent/ES2449268T3/en active Active
- 2006-08-18 PT PT101550580T patent/PT2194043E/en unknown
- 2006-08-18 JP JP2008527189A patent/JP5203203B2/en not_active Expired - Fee Related
- 2006-08-18 CN CN2006800384541A patent/CN101291909B/en not_active Expired - Fee Related
- 2006-08-18 EP EP11150041A patent/EP2364970A1/en not_active Withdrawn
- 2006-08-18 ES ES06813568T patent/ES2344156T3/en active Active
- 2006-08-18 AT AT06813568T patent/ATE463480T1/en active
- 2006-08-18 PL PL10155058T patent/PL2194043T3/en unknown
- 2006-08-18 SI SI200631745T patent/SI2194043T1/en unknown
- 2006-08-18 CN CN2011102403592A patent/CN102382170A/en active Pending
- 2006-08-18 EP EP11150039A patent/EP2357170A1/en not_active Withdrawn
- 2006-08-18 EP EP06813568A patent/EP1934179B1/en not_active Not-in-force
- 2006-08-18 AU AU2006279357A patent/AU2006279357B2/en not_active Ceased
- 2006-08-18 DK DK06813568.0T patent/DK1934179T3/en active
- 2006-08-18 DK DK10155058.0T patent/DK2194043T3/en active
- 2006-08-18 AR ARP060103610A patent/AR058025A1/en unknown
- 2006-08-18 EP EP10155058.0A patent/EP2194043B1/en not_active Not-in-force
- 2006-08-18 KR KR1020147013418A patent/KR20140069370A/en not_active Application Discontinuation
- 2006-08-18 TW TW095130511A patent/TWI391376B/en not_active IP Right Cessation
- 2006-08-18 PL PL06813568T patent/PL1934179T4/en unknown
- 2006-08-18 SI SI200630710T patent/SI1934179T1/en unknown
- 2006-08-18 RU RU2008110479/04A patent/RU2446171C2/en not_active IP Right Cessation
- 2006-08-18 TW TW101126397A patent/TW201245149A/en unknown
- 2006-08-18 NZ NZ593214A patent/NZ593214A/en not_active IP Right Cessation
- 2006-08-18 SG SG2014013338A patent/SG2014013338A/en unknown
- 2006-08-18 KR KR1020137005426A patent/KR20130038947A/en not_active Application Discontinuation
- 2006-08-18 PL PL385229A patent/PL385229A1/en not_active Application Discontinuation
- 2006-08-18 NZ NZ604087A patent/NZ604087A/en not_active IP Right Cessation
- 2006-08-18 US US11/506,550 patent/US7776887B2/en not_active Expired - Fee Related
- 2006-08-18 CA CA002619659A patent/CA2619659A1/en not_active Abandoned
- 2006-08-18 BR BRPI0615029-2A patent/BRPI0615029A2/en not_active IP Right Cessation
- 2006-08-18 PT PT06813568T patent/PT1934179E/en unknown
- 2006-08-18 DE DE602006013492T patent/DE602006013492D1/en active Active
- 2006-08-18 NZ NZ566049A patent/NZ566049A/en not_active IP Right Cessation
- 2006-08-18 WO PCT/US2006/032481 patent/WO2007022459A2/en active Application Filing
-
2008
- 2008-02-18 IL IL189585A patent/IL189585A/en not_active IP Right Cessation
- 2008-02-25 ZA ZA200801791A patent/ZA200801791B/en unknown
- 2008-03-18 KR KR1020087006558A patent/KR101474405B1/en not_active IP Right Cessation
- 2008-12-23 HK HK08113896.0A patent/HK1122801A1/en not_active IP Right Cessation
-
2010
- 2010-03-15 US US12/661,319 patent/US8637457B2/en not_active Expired - Fee Related
- 2010-07-05 CY CY20101100613T patent/CY1110214T1/en unknown
- 2010-12-09 HK HK10111510.6A patent/HK1145022A1/en not_active IP Right Cessation
-
2011
- 2011-11-29 RU RU2011148615/04A patent/RU2011148615A/en not_active Application Discontinuation
-
2013
- 2013-10-07 IL IL228770A patent/IL228770A0/en unknown
- 2013-12-17 US US14/109,631 patent/US20140107318A1/en not_active Abandoned
-
2014
- 2014-02-25 CY CY20141100149T patent/CY1114916T1/en unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL228770A0 (en) | Processes and intermaediates | |
EP1920216A4 (en) | Location signposting and orientation | |
IL185280A0 (en) | Tetrahydroindolone and tetrahydroindazolone derivatives | |
IL189252A0 (en) | Dihydroxyanthraquinones and their use | |
IL185223A0 (en) | Compounds and uses thereof | |
EP1753468A4 (en) | Carboranylporphyrins and uses thereof | |
GB0502979D0 (en) | Biomarkers and uses thereof | |
EP1778082A4 (en) | Carboranylporphyrins and uses thereof | |
EP1938123A4 (en) | Up-armoring structure and method | |
GB0509427D0 (en) | Nano-construction processes and analytical processes | |
GB0521992D0 (en) | System design and manufacture | |
GB0520935D0 (en) | Integrated processor-template-system and project | |
GB0511807D0 (en) | Process and compound | |
GB0523637D0 (en) | Process and compounds | |
GB0502978D0 (en) | Biomarkers and uses thereof | |
GB0502843D0 (en) | Jig-was and jig-will | |
GB0517239D0 (en) | Geogrotren-mk1-system and project | |
GB0517240D0 (en) | Chronorotron mk1-system and project | |
GB0522259D0 (en) | e-s-spi-l-d-film-cinema-back-engineering armageddon-system and project | |
GB0518875D0 (en) | Methods and means | |
GB0514416D0 (en) | Compounds and uses thereof | |
GB0521272D0 (en) | Compounds and uses thereof | |
HU0500519D0 (en) | New process and intermediate | |
GB0506545D0 (en) | Compounds and their uses | |
GB0510263D0 (en) | Compounds and their uses |